Histone peptide-induced nasal tolerance: suppression of murine lupus

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Induced mucosal tolerance has been shown to be beneficial in preventing or treating a number of murine and human autoimmune disorders. However, this particular form of therapy has not been thoroughly tested in systemic lupus erythematosus. In this study, we investigated the conditions for induction of nasal tolerance using a histone peptide named H471 expressing a dominant T cell epitope in the histone protein H4 of mononucleosome in lupus-prone SNF1 female mice. We also tested the effect of chronic peptide nasal treatment on the development of autoimmune reactivities in these mice. Results demonstrated that a dose-dependent nasal tolerance to peptide H471 can be achieved before or after peptide sensitization in SNF1 mice. In addition, tolerance to mononucleosomes was induced by nasal instillation of SNF, mice with H471. This was accompanied by an increase in IL-10 and suppression of IFN-gamma production by lymph node cells. Suppression of Th1-type cytokines was also observed in SNF1 mice that were nasally administered with H471 before intradermal injection with the peptide. Finally, chronic nasal instillation of mice with the H471 peptide not only suppressed the development of autoantibodies, but also altered the severity of glomerulonephritis in lupus-prone SNF1 mice.

Original languageEnglish
Pages (from-to)1126-1134
Number of pages8
JournalThe Journal of Immunology
Volume169
Issue number2
Publication statusPublished - 2002

Keywords

  • LYMPHOCYTE-ASSOCIATED ANTIGEN-4
  • COLLAGEN-INDUCED ARTHRITIS
  • REGULATORY T-CELLS
  • ORAL TOLERANCE
  • AUTOIMMUNE ENCEPHALOMYELITIS
  • IN-VIVO
  • B-CELL
  • MICE
  • INDUCTION
  • AUTOANTIBODIES

Cite this

Histone peptide-induced nasal tolerance: suppression of murine lupus. / Ward, Frank James.

In: The Journal of Immunology, Vol. 169, No. 2, 2002, p. 1126-1134.

Research output: Contribution to journalArticle

@article{b2af0cae0864416493552c7f46adda85,
title = "Histone peptide-induced nasal tolerance: suppression of murine lupus",
abstract = "Induced mucosal tolerance has been shown to be beneficial in preventing or treating a number of murine and human autoimmune disorders. However, this particular form of therapy has not been thoroughly tested in systemic lupus erythematosus. In this study, we investigated the conditions for induction of nasal tolerance using a histone peptide named H471 expressing a dominant T cell epitope in the histone protein H4 of mononucleosome in lupus-prone SNF1 female mice. We also tested the effect of chronic peptide nasal treatment on the development of autoimmune reactivities in these mice. Results demonstrated that a dose-dependent nasal tolerance to peptide H471 can be achieved before or after peptide sensitization in SNF1 mice. In addition, tolerance to mononucleosomes was induced by nasal instillation of SNF, mice with H471. This was accompanied by an increase in IL-10 and suppression of IFN-gamma production by lymph node cells. Suppression of Th1-type cytokines was also observed in SNF1 mice that were nasally administered with H471 before intradermal injection with the peptide. Finally, chronic nasal instillation of mice with the H471 peptide not only suppressed the development of autoantibodies, but also altered the severity of glomerulonephritis in lupus-prone SNF1 mice.",
keywords = "LYMPHOCYTE-ASSOCIATED ANTIGEN-4, COLLAGEN-INDUCED ARTHRITIS, REGULATORY T-CELLS, ORAL TOLERANCE, AUTOIMMUNE ENCEPHALOMYELITIS, IN-VIVO, B-CELL, MICE, INDUCTION, AUTOANTIBODIES",
author = "Ward, {Frank James}",
year = "2002",
language = "English",
volume = "169",
pages = "1126--1134",
journal = "The Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "2",

}

TY - JOUR

T1 - Histone peptide-induced nasal tolerance: suppression of murine lupus

AU - Ward, Frank James

PY - 2002

Y1 - 2002

N2 - Induced mucosal tolerance has been shown to be beneficial in preventing or treating a number of murine and human autoimmune disorders. However, this particular form of therapy has not been thoroughly tested in systemic lupus erythematosus. In this study, we investigated the conditions for induction of nasal tolerance using a histone peptide named H471 expressing a dominant T cell epitope in the histone protein H4 of mononucleosome in lupus-prone SNF1 female mice. We also tested the effect of chronic peptide nasal treatment on the development of autoimmune reactivities in these mice. Results demonstrated that a dose-dependent nasal tolerance to peptide H471 can be achieved before or after peptide sensitization in SNF1 mice. In addition, tolerance to mononucleosomes was induced by nasal instillation of SNF, mice with H471. This was accompanied by an increase in IL-10 and suppression of IFN-gamma production by lymph node cells. Suppression of Th1-type cytokines was also observed in SNF1 mice that were nasally administered with H471 before intradermal injection with the peptide. Finally, chronic nasal instillation of mice with the H471 peptide not only suppressed the development of autoantibodies, but also altered the severity of glomerulonephritis in lupus-prone SNF1 mice.

AB - Induced mucosal tolerance has been shown to be beneficial in preventing or treating a number of murine and human autoimmune disorders. However, this particular form of therapy has not been thoroughly tested in systemic lupus erythematosus. In this study, we investigated the conditions for induction of nasal tolerance using a histone peptide named H471 expressing a dominant T cell epitope in the histone protein H4 of mononucleosome in lupus-prone SNF1 female mice. We also tested the effect of chronic peptide nasal treatment on the development of autoimmune reactivities in these mice. Results demonstrated that a dose-dependent nasal tolerance to peptide H471 can be achieved before or after peptide sensitization in SNF1 mice. In addition, tolerance to mononucleosomes was induced by nasal instillation of SNF, mice with H471. This was accompanied by an increase in IL-10 and suppression of IFN-gamma production by lymph node cells. Suppression of Th1-type cytokines was also observed in SNF1 mice that were nasally administered with H471 before intradermal injection with the peptide. Finally, chronic nasal instillation of mice with the H471 peptide not only suppressed the development of autoantibodies, but also altered the severity of glomerulonephritis in lupus-prone SNF1 mice.

KW - LYMPHOCYTE-ASSOCIATED ANTIGEN-4

KW - COLLAGEN-INDUCED ARTHRITIS

KW - REGULATORY T-CELLS

KW - ORAL TOLERANCE

KW - AUTOIMMUNE ENCEPHALOMYELITIS

KW - IN-VIVO

KW - B-CELL

KW - MICE

KW - INDUCTION

KW - AUTOANTIBODIES

M3 - Article

VL - 169

SP - 1126

EP - 1134

JO - The Journal of Immunology

JF - The Journal of Immunology

SN - 0022-1767

IS - 2

ER -